Journal Club - DAPA-HF trial by de Louw, PGY-3, Emma
Thomas Jefferson University 
Jefferson Digital Commons 
Department of Family & Community Medicine 
Presentations and Grand Rounds Department of Family & Community Medicine 
9-24-2020 
Journal Club - DAPA-HF trial 
Emma de Louw, PGY-3 
Thomas Jefferson University 
Follow this and additional works at: https://jdc.jefferson.edu/fmlectures 
 Part of the Family Medicine Commons, and the Primary Care Commons 
Let us know how access to this document benefits you 
Recommended Citation 
de Louw, PGY-3, Emma, "Journal Club - DAPA-HF trial" (2020). Department of Family & 
Community Medicine Presentations and Grand Rounds. Paper 445. 
https://jdc.jefferson.edu/fmlectures/445 
This Article is brought to you for free and open access by the Jefferson Digital Commons. The Jefferson Digital 
Commons is a service of Thomas Jefferson University's Center for Teaching and Learning (CTL). The Commons is 
a showcase for Jefferson books and journals, peer-reviewed scholarly publications, unique historical collections 
from the University archives, and teaching tools. The Jefferson Digital Commons allows researchers and interested 
readers anywhere in the world to learn about and keep up to date with Jefferson scholarship. This article has been 
accepted for inclusion in Department of Family & Community Medicine Presentations and Grand Rounds by an 
authorized administrator of the Jefferson Digital Commons. For more information, please contact: 
JeffersonDigitalCommons@jefferson.edu. 
Journal Club
-
DAPA-HF trial
Emma de Louw, PGY-3
9/24/20
Disclosures
I have no disclosures
Outline
● Heart failure background
● Overview SGLT-2 inhibitor
● Previous evidence
● DAPA-HF trial
○ Aim
○ Methods
○ Results
○ Limitations
○ Conclusion
● Future directions
● Translate to JFMA
Heart failure
● ~6.2 million adults in the US
● High costs: $30.7 billion (‘12)
● Treatment guidelines HFrEF 
(2017):
Beta blocker + diuretic + 
ACEi/ARB/ARNI

SGLT-2 inhibitors
● Block glucose reabsorption 
in blood
● Increased urinary glucose & 
sodium  secretion
● Side effects:
○ Increased UTI
○ Genital mycotic infections
○ Increased risk of DKA
○ Fournier’s gangrene
○ AKI
○ Hypotension, dehydration

SGLT-2 inhibitors
“Gliflozins”:
● Canagliflozin (Invokana)
● Dapagliflozin (Farxiga)
● Empagliflozin (Jardiance)
● Ertugliflozin (Steglatro)

Previous evidence
● SGLT2 inhibitors decrease risk of first 
hospitalization for heart failure in patients 
with DM2 (25 - 35%) = prevention
● CANVAS + EMPA-REG: mechanisms CV 
benefit likely driven by reduced HF death
● EMPA-REG OUTCOME:  reduced risk of 
pump failure and sudden deaths
● DECLARE-TIMI 58: no reduction in major 
adverse CV events, but reduction in CV 
death or HF hospitalization (Esp. HFrEF)
→ Can SGLT-2 inhibitors treat HFrEF?
● Benefits on HF could not be explained by 
diuretic or anti-hyperglycemic effects
● Benefits may be mediated by the 
inhibition of sodium-hydrogen exchange 
rather than the effect on glucose 
reabsorption
● Reduced cardiac injury, hypertrophy, 
fibrosis, systolic dysfunction
→ Will it work for patients without DM?
Previous evidence

Aim
“To prospectively evaluate the efficacy and safety of the SGLT2 inhibitor 
dapagliflozin in patients with heart failure and a reduced ejection fraction, 
regardless of the presence or absence of diabetes”
Methods
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Methods - Trial design
● Phase 3, Randomized, Double-Blinded
● Placebo-controlled
○ Dapagliflozin 10 mg vs Placebo
○ + Conventional HF therapy
● 410 centers in 20 countries
● N = 4744
● Stratification: DM2 (A1c ≥ 6.5%)
● Median follow up time: 18.2 months
○ 14 days, 60 days, q4 months
● In collaboration with sponsor: AstraZeneca
○ Analyses replicated by independent academic group
Clinical Trials
Methods - Patients
Inclusion criteria:
● Age ≥ 18 years
● EF ≤ 40%
● NYHA class II-IV
● NT-proBNP ≥ 600 pg/ml 
○ or ≥ 400 pg/ml if HF hospitalization in previous 12 mo)
○ Afib or Aflutter: NT-proBNP ≥ 900 mg/ml
● Standard treatment for heart failure
○ Device: ICD, cardiac resynchronization therapy, or both
○ Meds: ACEi, ARB, sacubitril-valsartan + beta-blocker +/- mineralocorticoid receptor antagonist
● DM: continued to take glucose-lowering therapy
○ Doses could be adjusted as required (insulin, sulfonylurea)
Methods - Patients
Exclusion criteria:
● Recent treatment with SGLT2 inhibitor
● Unacceptable side effects associated with SGLT2 inhibitor
● DM type 1
● Symptomatic hypotension or SBP < 95 mmHg
● eGFR ≤ 30



Methods - Outcomes
Primary outcome:
● Composite of worsening heart failure or death from cardiovascular causes
○ Hospitalization
○ Urgent visit resulting in IV therapy for HF
Methods - Outcomes
Secondary outcomes:
● Composite of hospitalization for heart failure or cardiovascular death
● Total number of hospitalizations for HF & cardiovascular deaths
● Change in symptoms
○ Kansas City Cardiomyopathy Questionnaire
● Composite of worsening renal function
○ ≥ 50% decline in eGFR, ESRD (eGFR≤ 15 for ≥ 28 days) , renal death
● Death from any cause
Methods - Outcomes
Safety analysis:
● Serious adverse events
● Adverse events associated with discontinuation of a trial treatment
● Adverse events of interest
○ Volume depletion
○ Renal events
○ Major hypoglycemic events
○ Bone fractures
○ DKA
○ Amputations
○ Fournier’s gangrene
● Abnormal lab findings of note *Data on other adverse events not routinely collected given 
extensive previous collection on safety data regarding dapagliflozin 
(Wiviott ea 2019)
Methods - Statistical Analysis
● Intention-to-treat analysis
● Time-to-event data: Kaplan-Meier estimates & cox proportional-hazards 
models
● Incidence of adverse events: Fisher’s exact test
Cox proportional hazards model
Relate several risk factors/exposures, considered simultaneously, to survival time
Effect measured: Hazard rate = Probability of an individual at time t has event 
happening at that time
Hazard Ratio = Probability of events in treatment group / probability of events in 
control group
Averaged over the whole follow-up period
HR ≠RR
→ Time to event
Results ● Efficacy Outcomes● Safety Outcomes

Primary outcome - Worsening HF or CV death
HR 0.74
Dapa → 26% less risk of 
developing worsening HF 
or CV death, at any time
NNT = 21
Secondary outcome - HF hospitalization
Secondary outcome - mortality
Efficacy outcomes
Effect by subgroups
Primary outcome - subgroup analysis
Effect by subgroups
Subgroup analysis - DM vs no DM
               Patients without DM2 (n=2605) Patients with DM2 (n-2139)
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Discussion
● When added to standard therapy, dapagliflozin reduced the risk of worsening 
HF events and CV death, and improved symptoms in patients with HFrEF,  both 
with and without DM
● Benefits occurred early after randomization
● Dapagliflozin was well tolerated 
○ <8% volume depletion or worsening kidney function
● Rate of treatment discontinuation due to adverse event was low (<5%)
→ Dapagliflozin offers new approach to treatment of HFrEF in 
patients with and without DM
& Appears to be safe
Discussion - Strengths
● RCT
● Large patient population 
● Multicenter trial across different 
countries 
○ Increased external validity
● Independent analyses from 
sponsor
● Follow up time 24 months
Discussion - Limitations
● Limited generalizability due to 
specific inclusion and exclusion 
criteria
● <5% black patients
● Few very elderly patients with 
multiple coexisting illnesses
● Few NYHA III or IV
● Women ~ 25%
● Mean BMI ~ 28
● Not included in AE: UTI’s, yeast infx
Mechanism of action?
Hypotheses:
● SGLT2 inhibitors mitigate glycemia-related cardiotoxicity
● Enhanced ketogenesis contributes to the benefit of heart failure
● Renal sodium excretion
● Increase in hematocrit favorable for CAD
○ Increase in hematocrit did not affect clinical course of pts with HF
DAPA-HF did not support the above hypotheses
FDA approval
● May 5 2020
● Dapagliflozin approved specifically for the treatment of patients with heart 
failure and a reduced ejection fraction
New Guidelines
Future directions
● EMPEROR-Reduced trial (NEJM,Aug 2020):  empagliflozin, more severe HF
○ Similar results
● RCT dapagliflozin vs empagliflozin
● Most effective dosage
● Mechanism of action
Practice implications for JFMA
● Dapagliflozin 10mg seems to be effective & safe for patients with mild-mod 
HFrEF in reducing worsening HF and death
● Additional data needed
○ More severe HF
○ More diverse patient population
○ Higher BMI
○ More comorbidities
● How to explain to our patients?
● High costs
○ Discount not for Medicare/Medicaid
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Questions?

Methods - Procedures
● 14 day screening period: baseline criteria, in- and exclusion criteria
● Random assignment to treatment vs placebo group
○ Dapagliflozin 10mg once daily
● Randomization: sequestered, fixed-randomization schedule; use of balanced 
blocks → 1:1 ratio
●
Methods - Procedures
60 days
Assessment of heart failure & 
volume status, adverse events, 
evaluation of renal function and 
potassium levels.
8 months
Reassess
14 days
Assessment of heart failure & 
volume status, adverse events, 
evaluation of renal function and 
potassium levels.
4 months
Reassess
12 months
Reassess
16- 24 months
Reassess
- Dapagliflozin or placebo discontinued if pregnancy, DKA
- Dose reduction or temporary discontinuation: if acute unexpected decline in eGFR, volume depletion or 
hypotension


MOA

Time to event
Hazard = instantaneous event rate
Probability of an individual at time t has event happening at that time
Hazard Ratio
Probability of events in treatment group / probability of events in control group
● HR =1 (at any time, event rates similar in both arms)
● HR 0.5 (at any time, half as many patients in treatment group are having an 
event proportionally to comparison group )
HR ≠RR
Relative Risk (Risk Ratio) = 
Risk (cumulative incidence) treatment group / risk placebo group
Relative Risk Reduction (efficacy) =  1-RR
Relative decrease in risk of event in exposed group compared to unexposed group
Absolute Risk Reduction
Disease risk in placebo group - disease risk in treatment group
NNT = 1/ARR
How many patients need treatment before 1 patient benefits

